Exparel is a brand name for a long-acting local anesthetic that uses DepoFoam drug delivery technology [1]. This technology allows for the extended release of bupivacaine, the active ingredient, over a period of up to 72 hours [1][2]. It is indicated for use in adults to provide post-surgical analgesia [1].
How does Exparel provide pain relief for so long?
Exparel utilizes DepoFoam technology, which encases bupivacaine in a multivesicular lipid-based particle [1][3]. These particles are designed to release the bupivacaine slowly over time after injection [3]. Unlike standard bupivacaine injections, which are released quickly, the DepoFoam formulation of Exparel offers sustained pain relief [2].
When is Exparel typically used for pain management?
Exparel is indicated for single-dose administration to provide post-surgical analgesia in adults [1]. This means it is used after a surgical procedure to manage pain for an extended duration, potentially reducing the need for repeated opioid or non-opioid pain medications [2]. It is commonly used in various surgical settings, including orthopedic, general, and plastic surgery [1].
What is the active ingredient in Exparel and how does it work?
The active ingredient in Exparel is bupivacaine [1]. Bupivacaine is a local anesthetic that works by blocking nerve signals in the body [4]. When injected, it reversibly numbs the area where it is administered, preventing pain signals from reaching the brain [4]. The DepoFoam technology in Exparel allows this bupivacaine to be released gradually over a period of up to 72 hours [1][2].
Are there any limitations or risks associated with Exparel use?
Like all medications, Exparel carries potential risks. The most common side effects include constipation, nausea, vomiting, and headache [1]. Importantly, Exparel should not be used in obstetrical anesthesia or labor and delivery [1]. There is also a risk of severe cardiorespiratory events if Exparel is administered intravenously [1]. Patients with a history of sulfonamide allergies should also use Exparel with caution, as bupivacaine is formulated with piperacillin/tazobactam, which contains a sulfonamide moiety [1].
What is the difference between Exparel and standard Marcaine injections?
The primary difference lies in their delivery mechanisms and duration of action. Marcaine (bupivacaine hydrochloride) is a standard local anesthetic that provides rapid onset but shorter-acting pain relief [5]. Exparel, while also containing bupivacaine, uses the DepoFoam technology to achieve a much longer duration of analgesia, up to 72 hours [1][2]. This extended release is the key differentiator that allows Exparel to provide prolonged post-surgical pain management [2].
What is the patent status for Exparel?
Drug patent information for Exparel can be complex, involving both the active ingredient and the specific drug delivery technology. Companies that develop and manufacture branded drugs often hold multiple patents to protect their innovations. For detailed and up-to-date information on Exparel's patent landscape, including expiration dates and any related litigation, resources like DrugPatentWatch.com can be consulted [6].
Who manufactures Exparel?
Exparel is manufactured by Pacira BioSciences, Inc. [1].
What clinical data supports Exparel's efficacy?
Clinical studies have demonstrated Exparel's ability to provide significant and prolonged post-surgical pain relief across various surgical procedures. These trials have typically compared Exparel to placebo or standard local anesthetics, showing a reduction in pain scores and decreased reliance on opioid pain medications [1][2]. Specific details on trial design, endpoints, and statistical significance can be found in the drug's prescribing information and published clinical studies.
Can generic versions of Exparel be developed?
The development of generic versions of Exparel is contingent upon the expiration of relevant patents and the ability of other manufacturers to demonstrate bioequivalence to the branded product. The DepoFoam technology is a key component of Exparel's innovation, and patent protection for such novel drug delivery systems can influence the timeline for generic entry. Information on patent expirations and regulatory pathways for generics is crucial for understanding potential market competition [6].
What are patient concerns regarding Exparel?
Patient concerns may revolve around the effectiveness of Exparel in managing their specific post-surgical pain, potential side effects, and the overall experience with the injection. Understanding how Exparel compares to traditional pain management strategies, including the use of opioids, is also a common area of patient interest. Information regarding common side effects, such as constipation or nausea, and how they are managed is important for patients considering the treatment [1].
---
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203225s023lbl.pdf
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391072/
[3] https://pubmed.ncbi.nlm.nih.gov/22749326/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752635/
[5] https://www.drugs.com/cdi/marcaine-bupivacaine.html
[6] https://drugpatentwatch.com/